Figures 9A–H shows that in the TARGET cohort, LAG3 (p = 1.3e-04), TIGIT (p = 0.023), TIM3 (p = 0.002), and CTLA4 (p = 0.029) expressions were down-regulated in the high-scoring group in comparison to the low-scoring group. On the other hand, as the PRS-score increased, the expression of LAG3 (p = 0.0035), TIM3 (p = 1.2e-04), IDO1 (p = 0.0082), CTLA4 (p = 0.0028), and PDCD1 (p = 0.0021) in patients with osteosarcoma also decreased in the GEO cohort (Figures 9I–P). This evidence concerns the gene HAVCR2 and osteosarcoma.